TABLE 3
Additive interactions of use of RAS inhibitors and statins for the risk of cancer in type 2 diabetes
| Measures of additive interaction of RAS inhibitors with statins* | Estimate (95% CI) |
|---|---|
| Model 1 | |
| RERI | 0.39 (0.09–0.69)† |
| AP | 1.57 (0.21–2.94)† |
| S | 0.66 (0.50–0.86) |
| Model 2 | |
| RERI | 0.53 (0.20–0.87)† |
| AP | 2.65 (0.38–4.91)† |
| S | 0.60 (0.46–0.78) |
-
*Adjusted schemes for models 1 and 2 are available in Table 2.
-
†Statistically significant with RERI > 0, AP > 0, and S > 1 indicating additive interaction.
